Chlorproguanil

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Chlorproguanil
Accession Number
DB12314
Description

Chlorproguanil has been used in trials studying the treatment of MALARIA. It is a dichloro-derivative of chloroguanide.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 288.18
Monoisotopic: 287.0704509
Chemical Formula
C11H15Cl2N5
Synonyms
  • Chlorproguanil
  • Chlorproguanilum
  • Clorproguanil

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetophenazineThe risk or severity of QTc prolongation can be increased when Chlorproguanil is combined with Acetophenazine.
AlimemazineThe risk or severity of QTc prolongation can be increased when Chlorproguanil is combined with Alimemazine.
ArtemetherThe risk or severity of QTc prolongation can be increased when Chlorproguanil is combined with Artemether.
ButaperazineThe risk or severity of QTc prolongation can be increased when Chlorproguanil is combined with Butaperazine.
ChlorpromazineThe risk or severity of QTc prolongation can be increased when Chlorproguanil is combined with Chlorpromazine.
DapsoneThe risk or severity of adverse effects can be increased when Chlorproguanil is combined with Dapsone.
FluphenazineThe risk or severity of QTc prolongation can be increased when Chlorproguanil is combined with Fluphenazine.
LumefantrineThe risk or severity of QTc prolongation can be increased when Chlorproguanil is combined with Lumefantrine.
MesoridazineThe risk or severity of QTc prolongation can be increased when Chlorproguanil is combined with Mesoridazine.
MethotrimeprazineThe risk or severity of QTc prolongation can be increased when Chlorproguanil is combined with Methotrimeprazine.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Purchasing individual compounds or compound libraries for your research?
Learn More
Product Ingredients
IngredientUNIICASInChI Key
Chlorproguanil hydrochloride6T04V14CU96001-93-0SVJMILFDDBKCGG-UHFFFAOYSA-N

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as dichlorobenzenes. These are compounds containing a benzene with exactly two chlorine atoms attached to it.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Halobenzenes
Direct Parent
Dichlorobenzenes
Alternative Parents
Biguanides / Aryl chlorides / Propargyl-type 1,3-dipolar organic compounds / Carboximidamides / Organopnictogen compounds / Organochlorides / Imines / Hydrocarbon derivatives
Substituents
1,2-dichlorobenzene / Aromatic homomonocyclic compound / Aryl chloride / Aryl halide / Biguanide / Carboximidamide / Guanidine / Hydrocarbon derivative / Imine / Organic 1,3-dipolar compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
8O3249M729
CAS number
537-21-3
InChI Key
ISZNZKHCRKXXAU-UHFFFAOYSA-N
InChI
InChI=1S/C11H15Cl2N5/c1-6(2)16-10(14)18-11(15)17-7-3-4-8(12)9(13)5-7/h3-6H,1-2H3,(H5,14,15,16,17,18)
IUPAC Name
1-[N'-(3,4-dichlorophenyl)carbamimidamido]-N-(propan-2-yl)methanimidamide
SMILES
CC(C)NC(=N)NC(=N)NC1=CC=C(Cl)C(Cl)=C1

References

General References
Not Available
PubChem Compound
9571037
PubChem Substance
347828579
ChemSpider
20950
ChEBI
135192
ChEMBL
CHEMBL1213553
ZINC
ZINC000000001136
PharmGKB
PA165857067
Wikipedia
Chlorproguanil

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentMalaria caused by Plasmodium falciparum2
3CompletedNot AvailableMalaria caused by plasmodium vivax / Plasmodium Infections1
3CompletedTreatmentFever / Plasmodium Infections1
3CompletedTreatmentMalaria caused by Plasmodium falciparum2
3CompletedTreatmentPlasmodium Infections2
3TerminatedTreatmentPlasmodium Infections1
2CompletedTreatmentPlasmodium Infections1
2, 3CompletedDiagnosticPlasmodium Infections1
1SuspendedTreatmentPlasmodium Infections1
Not AvailableCompletedPreventionAnemia / Plasmodium Infections1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0808 mg/mLALOGPS
logP2.88ALOGPS
logP2.99ChemAxon
logS-3.6ALOGPS
pKa (Strongest Basic)10ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area83.79 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity96.46 m3·mol-1ChemAxon
Polarizability28.87 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 15:55 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates